Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Preparing to launch asciminib, the first STAMP inhibitor with potential to transform the standard of care in CML Asciminib Ph3 study in 3L+ CML: Nearly doubled MMR rate at Week 24 % of patients 25.5% ~2x1 13.2% Asciminib N=157 Bosutinib N=76 Unmet need in later lines of CML remains high ■ ~15% of CML patients progress to 3L ☐ Up to 55% of patients are intolerant to a previous TKI Ready to launch the first STAMP² inhibitor in H1 2022 ■ 75% aided awareness on asciminib / MoA ahead of launch ■ Submissions to FDA and EMA in 3L CML achieved in June 2021 ■ 2 FDA BTDs, RTOR and Fast Track designation received Blockbuster potential in 3L CML (incl. T3151) Potential to provide the best benefit-risk profile in 1L CML ☐ ■ ~50% of patients relapse on imatinib or are refractory/intolerant to imatinib³ >30% of patients suffer from TKI-related non-hematological AES4 In earlier lines of CML treatment, asciminib may prevent resistance to currently available TKIs by combatting emergence of mutations at BCR-ABL1 ATP binding site Initiating Ph3 study of asciminib vs. investigator-selected TKI; FPFV in Q4 2021 See slide 55 for references. 30 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation